NPPA and hydrops fetalis: The next year, the results of the PRAISE-2 HF trial (The New York Heart Association (NYHA) Functional Classification—NYHA class III-IV; end point mortality or transplantation) indicated that the change in ST2 remained significant as a predictor of mortality or transplantation independent of BNP and proANP [9].